AN2 Therapeutics Overview
Valuation check: ANTX's PEG ratio is -18.96, below the sector sector average of 6.76.
Get informed when a big investor buys or sells
+ Follow-18.96
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for ANTX is -18.96. That is below the sector sector average of 6.76. Investors often review this figure alongside AN2 Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, ANTX currently prints -18.96 for PEG ratio, while the sector average sits near 6.76. That is roughly 380.5% below the sector mean. Large gaps often invite a closer look at AN2 Therapeutics's growth, margins, and balance sheet.
A PEG ratio of -18.96 for AN2 Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (6.76) and with ANTX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ANTX's PEG ratio (-18.96), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
